Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | The importance of induction chemotherapy in the AML treatment

Jeffrey Lancet • 2 Sep 2021
SOHO 2021
Acute Myeloid Leukemia Leukemia Antibodies CPX-351 Cytarabine Daunorubicin Gemtuzumab ozogamicin

Jeffrey Lancet, MD, of Moffitt Cancer Center, Tampa, FL, gives an overview of the importance of induction chemotherapy in the treatment of acute myeloid leukemia (AML). Whilst induction chemotherapy remains the standard of care in most patients with AML, older patients may benefit more from hypomethylating agents as primary treatment. Dr Lancet also discusses the therapeutic use of CPX-351, a liposomal formulation of cytarabine and daunorubicin, as a bridge to curative transplant. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

More from Jeffrey Lancet

4:48
Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory
Jeffrey Lancet • 8 Dec 2023
5:17
COVALENT-101: investigating menin inhibition with BMF-219 for treating patients with R/R AML or ALL
Jeffrey Lancet • 8 Dec 2023
1:45
The impact of secondary-type mutations in NPM1-mutated AML
Jeffrey Lancet • 11 Dec 2021
6:57
Responses to COVID-19 vaccines in patients with AML and MDS
Jeffrey Lancet • 11 Dec 2021

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals